Abstract
The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Current Drug Targets
Title: Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Volume: 10 Issue: 4
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis, Genovefa D. Kolovou and Dimitri P. Mikhailidis
Affiliation:
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Abstract: The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios, Karagiannis Asterios, Kolovou D. Genovefa and Mikhailidis P. Dimitri, Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846425
DOI https://dx.doi.org/10.2174/138945009787846425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Wound with Diabetes: Present Scenario and Future
Current Diabetes Reviews The Effect of Glucose-Insulin-Potassium (GIK) Infusion on Cardiovascular Function and Inflammation: Results from a Phase 1 Pilot Interventional Trial
Applied Clinical Research, Clinical Trials and Regulatory Affairs Evidence for, and Importance of, cGMP-Independent Mechanisms with NO and NO Donors on Blood Vessels and Platelets
Current Vascular Pharmacology Modulation of Apoptosis: New Opportunities for Drug Discovery to Treat Autoimmune Thyroiditis
Recent Patents on Inflammation & Allergy Drug Discovery Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Metabolism of Flavonoids in Human: A Comprehensive Review
Current Drug Metabolism Targets for Medical Therapy to Limit Abdominal Aortic Aneurysm Progression
Current Drug Targets Acute Decompensated Heart Failure Update
Current Cardiology Reviews ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Review of Characteristics, Pharmacology, Determination and Pharmacokinetics of Rhaponticin
Mini-Reviews in Organic Chemistry Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Prognostic Value of Coronary Artery Calcification
Vascular Disease Prevention (Discontinued) Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome
Current Pharmaceutical Biotechnology Subject Index To Volume 4
Current Vascular Pharmacology Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology New Insights into the Intracellular Mechanisms by Which PGI2 Analogues Elicit Vascular Relaxation: Cyclic AMP-Independent, Gs-Protein Mediated-Activation of MaxiK Channel
Current Medicinal Chemistry - Cardiovascular & Hematological Agents